Your browser doesn't support javascript.
loading
Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study.
Nolan, Claire M; Polgar, Oliver; Schofield, Susie J; Patel, Suhani; Barker, Ruth E; Walsh, Jessica A; Ingram, Karen A; George, Peter M; Molyneaux, Philip L; Maher, Toby M; Man, William D-C.
Afiliación
  • Nolan CM; Harefield Respiratory Research Group, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; National Heart and Lung Institute, Imperial College London, London, England; Brunel University London, College of Health Medicine and Life Sciences, London,
  • Polgar O; Harefield Respiratory Research Group, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England.
  • Schofield SJ; National Heart and Lung Institute, Imperial College London, London, England.
  • Patel S; Harefield Respiratory Research Group, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; National Heart and Lung Institute, Imperial College London, London, England.
  • Barker RE; Harefield Respiratory Research Group, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; National Heart and Lung Institute, Imperial College London, London, England; Wessex Academic Health Science Network, Southampton, England.
  • Walsh JA; Harefield Respiratory Research Group, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England.
  • Ingram KA; Harefield Pulmonary Rehabilitation Unit, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England.
  • George PM; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; National Heart and Lung Institute, Imperial College London, London, England.
  • Molyneaux PL; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; National Heart and Lung Institute, Imperial College London, London, England.
  • Maher TM; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; National Heart and Lung Institute, Imperial College London, London, England; Keck School of Medicine, University of Southern California, Los Angeles, CA.
  • Man WD; Harefield Respiratory Research Group, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; Harefield Pulmonary Rehabilitation Unit, Royal Brompton and Harefield Clinical Group, Guy's and St. Thomas' NHS Foundation Trust, London, England; National
Chest ; 161(3): 728-737, 2022 03.
Article en En | MEDLINE | ID: mdl-34699771
ABSTRACT

BACKGROUND:

The adherence to and clinical efficacy of pulmonary rehabilitation in idiopathic pulmonary fibrosis (IPF), particularly in comparison with COPD, remains uncertain. The objectives of this real-world study were to compare the responses of patients with IPF with a matched group of patients with COPD undergoing the same supervised, outpatient pulmonary rehabilitation program and to determine whether pulmonary rehabilitation is associated with survival in IPF. RESEARCH QUESTION Do people with IPF improve to the same extent with pulmonary rehabilitation as a matched group of individuals with COPD, and are noncompletion of or nonresponse to pulmonary rehabilitation, or both, associated with 1-year all-cause mortality in IPF? STUDY DESIGN AND

METHODS:

Using propensity score matching, 163 patients with IPF were matched 11 with a control group of 163 patients with COPD referred for pulmonary rehabilitation. We compared between-group pulmonary rehabilitation completion rates and response. Survival status in the IPF cohort was recorded over 1 year after pulmonary rehabilitation discharge. Cox proportional hazards regression explored the association between pulmonary rehabilitation status and all-cause mortality.

RESULTS:

Similar pulmonary rehabilitation completion rates (IPF, 69%; COPD, 63%; P = .24) and improvements in exercise response were observed in both groups with no significant mean between-group differences in incremental shuttle walk test (ISWT) change (mean, 2 m [95% CI, -18 to 22 m]). Pulmonary rehabilitation noncompletion (hazard ratio [HR], 5.62 [95% CI, 2.24-14.08]) and nonresponse (HR, 3.91 [95% CI, 1.54-9.93]) were associated independently with increased 1-year all-cause mortality in IPF.

INTERPRETATION:

This real-word study demonstrated that patients with IPF have similar completion rates and magnitude of response to pulmonary rehabilitation compared with a matched group of patients with COPD. In IPF, noncompletion of and nonresponse to pulmonary rehabilitation were associated with increased all-cause mortality. These data reinforce the benefits of pulmonary rehabilitation in patients with IPF.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad Pulmonar Obstructiva Crónica / Fibrosis Pulmonar Idiopática Tipo de estudio: Prognostic_studies Idioma: En Revista: Chest Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad Pulmonar Obstructiva Crónica / Fibrosis Pulmonar Idiopática Tipo de estudio: Prognostic_studies Idioma: En Revista: Chest Año: 2022 Tipo del documento: Article